[{"data":1,"prerenderedAt":186},["ShallowReactive",2],{"drug-febuxostat":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":69,"warnings":79,"renal":87,"monitoring":88,"interactions":89,"review":97,"examples":100,"atc":106,"iran":108,"usApproval":128,"links":134,"populations":150},"febuxostat",1,{"fa":7,"en":8},"فبوکسوستات","Febuxostat","musculoskeletal",{"fa":11,"en":12},"مهارکننده گزانتین اکسیداز","Xanthine oxidase inhibitor",[14],{"name":15,"market":16},"Uloric","US",[18,19,7],"uloric","adenuric",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-40","tablet","oral","40 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},40,"mg",false,[16],[32],{"source":33,"section":34},"fda-febuxostat","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-80","80 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},80,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":45,"label":46,"population":49,"type":53,"unit":28,"dose":54,"refs":55,"limits":58,"notes":61},"gout",{"fa":47,"en":48},"هیپراوریسمی مزمن در نقرس — شروع ۴۰ mg یک بار در روز (تا ۸۰ mg)","Chronic hyperuricaemia in gout — start 40 mg once daily (up to 80 mg)",{"minAge":50},{"value":51,"unit":52},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[56],{"source":33,"section":57},"2.1",{"maxPerDose":39,"refs":59},[60],{"source":33,"section":57},[62],{"text":63,"refs":66},{"fa":64,"en":65},"اگر پس از ۲ هفته اسید اوریک زیر ۶ نشد، ۸۰ mg. نارسایی شدید کلیه: حداکثر ۴۰ mg. در شروع درمان پیشگیری از حمله (NSAID یا کلشی‌سین).","If uric acid is not \u003C6 after 2 weeks, 80 mg. Severe renal impairment: max 40 mg. Flare prophylaxis (NSAID or colchicine) when starting.",[67],{"source":33,"section":68},"2",[70],{"id":71,"severity":72,"text":73,"refs":76},"ci","block",{"fa":74,"en":75},"مصرف همزمان آزاتیوپرین یا مرکاپتوپورین.","Concomitant azathioprine or mercaptopurine.",[77],{"source":33,"section":78},"4",[80],{"text":81,"refs":84},{"fa":82,"en":83},"هشدار جعبه‌ای: مرگ قلبی‌عروقی در بیماران نقرس با بیماری قلبی بیشتر از آلوپورینول؛ فقط اگر آلوپورینول مؤثر یا قابل تحمل نیست.","Boxed warning: higher cardiovascular death than allopurinol in gout patients with CV disease; use only when allopurinol fails or is not tolerated.",[85],{"source":33,"section":86},"Boxed Warning",[],[],[90],{"with":91,"text":92,"refs":95},"azathioprine",{"fa":93,"en":94},"آزاتیوپرین و مرکاپتوپورین — ممنوع (افزایش سطح و سمیت).","Azathioprine and mercaptopurine — contraindicated (raised levels and toxicity).",[96],{"source":33,"section":78},{"status":98,"reviewer":99,"date":99},"unverified",null,[101],{"regimen":45,"formulation":22,"input":102,"expect":105},{"ageYears":103,"weightKg":104},55,85,{"perDose":27,"tabletsPerDoseRounded":5},[107],"M04AA03",{"status":109,"forms":110,"refs":123},"registered",[111,115,119],{"code":112,"en":113,"fa":114},"16693","FEBUXOSTAT 40MG TAB","قرص فبوکسوستات ۴۰ میلی‌گرم",{"code":116,"en":117,"fa":118},"19835","FEBUXOSTAT 80MG TAB","قرص فبوکسوستات ۸۰ میلی‌گرم",{"code":120,"en":121,"fa":122},"25137","FEBUXOSTAT 120 mg TABLET","قرص فبوکسوستات ۱۲۰ میلی‌گرم",[124],{"source":125,"section":126,"url":127},"darooyab-generic","G-4752\u002FFebuxostat","https:\u002F\u002Fwww.darooyab.ir\u002FG-4752\u002FFebuxostat",{"kind":129,"refs":130,"id":133},"ANDA",[131],{"source":33,"section":132},"SPL approval \u002F marketing category","ANDA213069",[135,138,142,145,148],{"kind":136,"url":137,"label":133},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=213069",{"kind":139,"url":140,"label":141},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=4f1d0452-e041-cda6-e063-6394a90a2aef","FDA Febuxostat",{"kind":143,"url":144,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609020.html",{"kind":146,"url":147,"label":107},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=M04AA03",{"kind":149,"url":127,"label":8},"darooyab",{"pregnancy":151,"lactation":160,"pediatric":168,"geriatric":177},{"level":152,"text":153,"quote":156,"refs":157},"caution",{"fa":154,"en":155},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited available data with febuxostat tablets use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes.",[158],{"source":33,"section":159},"8.1",{"level":152,"text":161,"quote":164,"refs":165},{"fa":162,"en":163},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of febuxostat in human milk, the effects on the breastfed infant, or the effects on milk production.",[166],{"source":33,"section":167},"8.2",{"level":169,"text":170,"quote":173,"refs":174},"not-established",{"fa":171,"en":172},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of febuxostat tablets in pediatric patients have not been established.",[175],{"source":33,"section":176},"8.4",{"level":178,"text":179,"quote":182,"refs":183},"ok",{"fa":180,"en":181},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dose adjustment is necessary in elderly patients.",[184],{"source":33,"section":185},"8.5",1792111453845]